ÀÓ»ó Á¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå : ¿öÅ©Ç÷οì À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² - ¿¹Ãø(2023³â-2030³â)
Clinical Oncology Next Generation Sequencing Market, By Workflow Type, By Technology, By Application, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1364700
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 269 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,474,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,401,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,778,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2022³â 3¾ï 8,840¸¸ ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2023³âºÎÅÍ 2030³â±îÁö CAGR 16.5%·Î È®´ë

ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ½ÃÀå ¿ªÇÐ

¾ÏÀÇ À¯º´·ü »ó½ÂÀÌ ÀÓ»ó Á¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾ÏÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áúº´À» ´õ ±íÀÌ ÀÌÇØÇÏ°í ½Å¾àÀ» ¹ß°ßÇÒ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì(NGS) ºÐ¼®Àº ÁøÇ༺ ¾Ï ȯÀÚÀÇ Ä¡·á¿¡ ±Þ¼ÓÈ÷ ¹Ù¶÷Á÷ÇÑ ¿É¼ÇÀ̵ǰí ÀÖ½À´Ï´Ù. NGS ºÐ¼®Àº ³ôÀº 󸮷®ÀÇ DNA ½ÃÄö½Ì ±â¼úÀ» »ç¿ëÇÏ¿© Àüü °Ô³ð, Àüü ¿¢¼Ø ¶Ç´Â ƯÁ¤ À¯ÀüÀÚ ¿¢¼Õ(Ç¥Àû ÆÐ³Î)ÀÇ ¼­¿­À» °áÁ¤ÇÕ´Ï´Ù. ¹Ì±¹¿¡¼­´Â 2020³â »õ·Ó°Ô 160¸¸ 3,844¸íÀÇ ¾Ï ȯÀÚ°¡ º¸°íµÇ¾î 60¸¸ 2,347¸íÀÌ ¾ÏÀ¸·Î »ç¸ÁÇß½À´Ï´Ù. Àα¸ 10¸¸¸í´ç 403¸íÀÇ ½Å±Ô ¾Ï Áõ·Ê°¡ º¸°íµÇ¾î 144¸íÀÌ ¾ÏÀ¸·Î »ç¸ÁÇß½À´Ï´Ù. Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ¿¡ µû¸£¸é, 2020³âÀº ÀÌȯÀ² µ¥ÀÌÅ͸¦ »ç¿ëÇÒ ¼ö ÀÖ´Â ÃÖ½Å ÇØÀÔ´Ï´Ù. ¶ÇÇÑ Â÷¼¼´ë ½ÃÄö½ÌÀº »õ·Î¿î ¾Ï ¿¬±¸ ¹ß°ßÀÇ ÀÔ±¸¸¦ ¿­¾î »õ·Î¿î ¾Ï ÁøÇà °æ·Î¿Í °úÁ¤À» ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù. À̰ÍÀº ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿É´Ï´Ù. ±×·¯³ª NGS ±â¼ú°ú ÀÎÇÁ¶ó¿¡ ÇÊ¿äÇÑ Ãʱâ ÅõÀÚ ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀÌ Á¦ÇÑµÉ ¼ö ÀÖÀ¸¸ç,

ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ¼¼±×¸ÕÅ×ÀÌ¼Ç ºÐ¼® :

¼¼°èÀÇ ÀÓ»ó Á¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀåÀº ¿öÅ©Ç÷οì À¯Çü, ¿ëµµ, ±â¼ú, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ¿öÅ©Ç÷ο¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. NGS »çÀü ½ÃÄö½º, NGS ½ÃÄö½º, NGS µ¥ÀÌÅÍ ºÐ¼®ÀÔ´Ï´Ù. NGS ½ÃÄö½Ì ºÎ¹®Àº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. NGS´Â ±âÁ¸ÀÇ Á¢±Ù¹ýº¸´Ù ÈξÀ ºü¸£°í Àú·ÅÇÑ DNA ¹× RNA ½ÃÄö½ÌÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ÇöÀç ½ÃÄö½Ì ±â¼úÀÇ ±×·ìÀ» ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¼ö¹é¸¸¿¡¼­ ¼ö½Ê¾ïÀÇ DNA ºÐÀÚÀÇ ¼­¿­À» µ¿½Ã¿¡ °áÁ¤ÇÏ´Â ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ±â¼ú¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Àüü °Ô³ð ½ÃÄö½º, Àüü ¿¢¼Ø ½ÃÄö½º, Ÿ°Ù ½ÃÄö½º ¹× Àç ½ÃÄö½º. Targeted Sequencing and resequencing ºÎ¹®Àº ½ÃÀå ¼ºÀåÀ» Áö¹èÇÕ´Ï´Ù. Ç¥Àû ½ÃÄö½ÌÀº ¸ðµç °Ô³ðÀ» ½ÃÄö½ÌÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó Áúº´°úÀÇ ¿¬°ü¼ºÀÌ È®ÀεǾú°Å³ª Áúº´°úÀÇ ¿¬°ü¼ºÀÌ ÀǽɵǴ ƯÁ¤ À¯ÀüÀÚ ¶Ç´Â °ü½É ¿µ¿ª¿¡ ÃÊÁ¡À» ¸ÂÃä´Ï´Ù. ÀÌÀü¿¡ ½ÃÄö½ÌµÈ DNAÀÇ ½ÃÄö½ÌÀ» Àç½ÃÄö½º¶ó°í ÇÕ´Ï´Ù. ¸ñÇ¥´Â ƯÈ÷ °ü½É ¿µ¿ª¿¡¼­ º¯ÇüÀ» ã´Â °ÍÀÔ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ½ºÅ©¸®´×, µ¿¹ÝÀÚ Áø´Ü ¹× ±âŸ Áø´Ü. ½ºÅ©¸®´× ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Á¾¾ç DNA¿Í »ý½Ä¼¼Æ÷ DNAÀÇ Â÷¼¼´ë ½ÃÄö½Ì(NGS)Àº Áø´Ü, ¿¹ÈÄ, Ä¡·áÀÇ Àǹ̸¦ ºü¸£°Ô È®ÀåÇÏ´Â Precision On ColologyÀÇ ±âÃÊÀÔ´Ï´Ù. Á¾¾çÇÐÀÇ Áø´Ü ¹× ½ºÅ©¸®´× ±â¼ú¿¡¼­ NGSÀÇ »ç¿ëÀº ½ÃÀåÀÇ »ó´çÇÑ È®´ë¸¦ °¡Á®¿É´Ï´Ù. NGS ÆÐ³Î, Àåºñ ¹× °ü·Ã ¼­ºñ½ºÀÇ ¿ä±¸´Â ±ØÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚ º°·Î º´¿ø, Ŭ¸®´Ð, ¿¬±¸¼ÒÀÇ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. °Ë»ç ½Ã¼³ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº Áø´Ü ½ÇÇè½ÇÀÌ NGS Ç÷§ÆûÀ» µµÀÔÇÏ¿© Á¾¾ç °Ô³ðÀ» ÇÁ·ÎÆÄÀϸµÇϰí, Àǻ簡 ½Ç¿ëÀûÀÎ µ¹¿¬º¯À̸¦ È®ÀÎÇÏ°í ±×¿¡ µû¶ó ÀǾàǰÀ» Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¸®ÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ Á¦°øÇÏ´Â ±¹°¡º°·Î ´õ ³ª´¹´Ï´Ù. ºÏ¹Ì´Â ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡¿Í ¾Ï ÀÌȯÀ² »ó½ÂÀ¸·Î ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀ» Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÏ¹Ì¿¡¼­´Â ¾ÏÀÇ ÀÌȯÀ²ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ »õ·Î¿î Áø´Ü¡¤Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹Ì±¹Àº ÀÇ·á ¹× »ý¸í°øÇÐ ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

°ø°ø ºÎ¹®°ú »ó¾÷ºÎ¹® ¸ðµÎ ¸Å³â ¼ö½Ê¾ï ´Þ·¯¸¦ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ¿© ½Å±â¼úÀÇ °³¼±°ú ¼ö¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àü¹Ì°úÇÐÀç´Ü ³» ±¹¸³°úÇбâ¼úÅë°è¼¾ÅÍ(NCSES)ÀÇ »õ·Î¿î µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ ÁøÇàµÈ ¿¬±¸°³¹ß(R&D)Àº 2020³â ÃÑ 7,170¾ï ´Þ·¯¿¡ À̸¨´Ï´Ù. À¯·´Àº »õ·Î¿î ÀÇ·á ±â¼úÀÇ Ä§Åõ°¡ ÁøÇàµÇ°í Àֱ⠶§¹®¿¡ ÀÓ»ó Á¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½ÌÀÇ 2À§ ½ÃÀåÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - °æÀï ±¸µµ:

Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼ú ½ÃÀåÀº Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ºÐ¾ßÀÇ ÀÇ»ç °áÁ¤ÀÚ´Â ÀûÀýÇÑ Àü·«°ú ±ÔÁ¦¸¦ ¼ö¸³Çϱâ À§ÇØ ½ÃÀå ¼ºÀå°ú ¹Ì·¡ µ¿Çâ¿¡ ´ëÇÑ »ç½ÇÀ» ¹ÙÅÁÀ¸·Î Áö½ÄÀÌ ÇÊ¿äÇÏÁö¸¸ ÀÌ·¯ÇÑ ÆÐÅÏÀÇ ¼º°Ý°ú ±Ô¸ð¿¡ ´ëÇØ °ÅÀÇ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¾Æ´Õ´Ï´Ù. ±â¾÷Àº ±× ÁöÀ§¸¦ ³ôÀ̱â À§ÇØ ÀÚÁÖ Á¦ÈÞ¿Í ÇÕº´À» ½Ç½ÃÇß½À´Ï´Ù. ´ë±â¾÷Àº ¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä«, ¾ÆÇÁ¸®Ä« µî ÃֽŠÀÇ·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â ½ÅÈï±¹¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº ½ÅÈï ±â¾÷µéÀÌ ½Å¼ÓÇÑ ½ÃÄö½Ì, ³ôÀº Á¤È®¼º ¹× ³·Àº °¡°ÝÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ½Å¼±ÇÑ ±â¼ú°ú Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Thermofisher ScientificÀº 2022³â 4¿ù 12ÀÏ CE-IVD ¸¶Å©¸¦ ȹµæÇÑ Ion Torrent Genexus Dx Integrated Sequencer¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½ÌÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ¾÷°èÀÇ Á¶»ç

Á¦5Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå : COVID-19ÁõÀÇ ¿µÇ⠺м®

Á¦6Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå »óȲ

Á¦7Àå ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ¿öÅ©Ç÷οì À¯Çüº°

Á¦8Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ±â¼úº°

Á¦9Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ¿ëµµº°

Á¦10Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ÀÓ»óÁ¾¾çÇÐÀÇ Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå-Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ÀÓ»óÁ¾¾çÇÐ Â÷¼¼´ë ½ÃÄö½Ì ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Clinical Oncology Next Generation Sequencing Market size was valued at USD 388.4 Million in 2022, expanding at a CAGR of 16.5% from 2023 to 2030.

Next-generation sequencing (NGS), also known as massively parallel sequencing, is a powerful method for capturing a vast quantity of genomic information about a tumor. The majority of NGS technologies rely on synthesis-based sequencing. NGS has recently been used in clinical oncology to advance individualized cancer treatment. NGS is utilized to find familial cancer mutation carriers, identify novel and rare cancer mutations, and offer molecular rationale for effective targeted therapy. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are generally expected to influence therapy selection to enhance patient outcomes.

Clinical Oncology Next Generation Sequencing Market- Market Dynamics

The rising prevalence of cancer is expected to drive the growth of the Clinical Oncology Next Generation Sequencing market.

As the prevalence of cancer rises, there is more need to better understand the disease and discover novel medicines. Next-generation sequencing (NGS) assays are quickly becoming the preferred option in the treatment of advanced cancer patients. NGS assays use high-throughput DNA sequencing technology to sequence the complete genome, the full exome, or certain gene exons (targeted panels). In the United States in 2020, 1,603,844 new cancer cases were reported and 602,347 people died of cancer. For every 100,000 people, 403 new cancer cases were reported and 144 people died of cancer. 2020 is the latest year for which incidence data are available, according to Centers for Disease Control and Prevention. Furthermore, Next Generation Sequencing opens the entrance to new oncological research discoveries, which may uncover new cancer progression pathways and processes. It provides growth opportunities for the market. However, the high cost of initial investment required for NGS technology and infrastructure can restrict market growth,

Clinical Oncology Next Generation Sequencing Market- Key Insights

Clinical Oncology Next Generation Sequencing Market- Segmentation Analysis:

The Global Clinical Oncology Next Generation Sequencing Market is segmented on the basis of Workflow Type, Application, Technology, End-User, and Region.

The market is divided into three categories based on Workflow: NGS Pre-Sequencing, NGS Sequencing, and NGS Data Analysis. The NGS Sequencing segment dominates the market. NGS refers to a class of current sequencing technologies that enable significantly faster and less expensive DNA and RNA sequencing than older approaches. These technologies have the ability to sequence millions to billions of DNA molecules at the same time.

The market is divided into three categories based on Technology: Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing and resequencing. Targeted Sequencing and resequencing segment dominates the market growth. Rather than sequencing the entire genome, targeted sequencing focuses on certain genes or regions of interest that have been linked to disease or are suspected to be linked to disease. The sequencing of previously sequenced DNA is referred to as resequencing. The purpose is to find variants, particularly in areas of interest.

The market is divided into two categories based on application: Screening, Companion Diagnostics, and other diagnostics. The Screening sector dominates the market and is likely to maintain its dominance during the forecast period. Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. The use of NGS in oncology diagnostic and screening techniques has resulted in significant market expansion. The need for NGS panels, equipment, and related services has increased dramatically.

The market is divided into three categories based on End-User: Hospitals, Clinics, and Laboratories. Laboratories dominate the market. Many diagnostic laboratories have implemented NGS platforms to provide tumor genomic profiling, assisting doctors in identifying actionable mutations and tailoring medicines accordingly.

Clinical Oncology Next Generation Sequencing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Clinical Oncology next-generation Sequencing market, due to increasing R&D investment, and the Rising Burden of Cancer. The increased incidence of cancer in North America needs novel diagnostic and treatment options. The United States invests much in medical and biotechnology research.

Both the public and commercial sectors invest billions of dollars in R&D each year, fueling improvements and the acceptance of new technology. New data from the National Center for Science and Engineering Statistics (NCSES) within the National Science Foundation indicate that research and experimental development (R&D) performed in the United States totaled USD 717.0 billion in 2020. Europe is expected to be the second-largest market for Clinical Oncology Generation Sequencing, due to increasing penetration of new medical technologies.

Clinical Oncology Next Generation Sequencing Market- Competitive Landscape:

The market for next-generation sequencing (NGS) technologies has expanded substantially. Decision-makers in health care require factual knowledge of market growth and future trends in order to design suitable strategies and regulations, yet little is known about the nature and magnitude of these patterns. Companies frequently collaborate or merge to boost their position. Major firms are expanding their presence into emerging countries in Asia, Latin America, and Africa, where there is a growing demand for modern medical technologies. Also, a number of startups bring fresh technology or approaches to the table, which may offer faster sequencing, higher accuracy, or lower prices. For example, On April 12, 2022, Thermo Fisher Scientific recently launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in one day.

Recent Developments:

In December 2021, Roche nowadays announced the launch of the AVENIO Edge System, a core component of Roche's strategy to advance sequencing technologies. Built on best-in-class foundational capabilities to deliver a fully automated, integrated sequencing solution. Roche is committed to developing diagnostic solutions with the goal of providing the healthcare community with faster and more accurate medical information to predict risk and detect disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET KEY PLAYERS

GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY WORKFLOW TYPE

GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY

GLOBAL CLINICAL ONCOLOGY NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION

GLOBAL CLINICAL ONCOLOGY NEXT-GENERATION SEQUENCING MARKET, BY END-USER

GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY REGION

Table of Contents

1. Clinical Oncology Next Generation Sequencing Market Overview

2. Executive Summary

3. Clinical Oncology Next Generation Sequencing Key Market Trends

4. Clinical Oncology Next Generation Sequencing Industry Study

5. Clinical Oncology Next Generation Sequencing Market: COVID-19 Impact Analysis

6. Clinical Oncology Next Generation Sequencing Market Landscape

7. Clinical Oncology Next Generation Sequencing Market - By Workflow Type

8. Clinical Oncology Next Generation Sequencing Market - By Technology

9. Clinical Oncology Next Generation Sequencing Market - By Application

10. Clinical Oncology Next Generation Sequencing Market - By End-User

11. Clinical Oncology Next Generation Sequencing Market- By Geography

12. Key Vendor Analysis- Clinical Oncology Next Generation Sequencing Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â